Tissue plasminogen activator prevents mortality from sulfur mustard analog-induced airway obstruction

American Journal of Respiratory Cell and Molecular Biology

Volumn 48, Issue 4, 2013, Pages 439-447

  Veress, Livia A ^a   Hendry Hofer, Tara B ^a   Loader, Joan E ^a   Rioux, Jacqueline S ^a   Garlick, Rhonda B ^a   White, Carl W ^a,b  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Airway obstruction; Fibrin; Plastic bronchitis; Sulfur mustard; Tissue plasminogen activator

Indexed keywords

BICARBONATE; FIBRIN; ISOFLURANE; MUSTARD GAS DERIVATIVE; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR; CHEMICAL WARFARE AGENT; FIBRINOLYTIC AGENT; MUSTARD GAS;

AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL GAS; ARTERIAL OXYGEN TENSION; ARTICLE; BICARBONATE BLOOD LEVEL; BRONCHITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FIBRINOLYSIS; GAS POISONING; HYPERCAPNIA; HYPOXEMIA; LACTIC ACIDOSIS; LUNG BURN; LUNG GAS EXCHANGE; MALE; MICRODISSECTION; MORTALITY; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN SATURATION; PULSE OXIMETRY; RAT; RESPIRATORY DISTRESS; SCORING SYSTEM; SHAM PROCEDURE; TISSUE OXYGENATION; TOXIC INHALATION; TRACHEOBRONCHIAL TREE; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; HUMAN; METABOLISM; PATHOLOGY; RESPIRATORY FAILURE; SPRAGUE DAWLEY RAT;

AIRWAY OBSTRUCTION; ANIMALS; CHEMICAL WARFARE AGENTS; DISEASE MODELS, ANIMAL; FIBRIN; FIBRINOLYTIC AGENTS; HUMANS; MUSTARD GAS; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY INSUFFICIENCY; TISSUE PLASMINOGEN ACTIVATOR;

MLCS; MLOWN;

EID: 84878253560     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0177OC     Document Type: Article

References (50)

1. Eisenmenger W, Drasch G, von Clarmann M, Kretschmer E, Roider G. Clinical and morphological findings on mustard gas [bis(2-chloroethyl) sulfide] poisoning. J Forensic Sci 1991;36: 1688-1698.
2. Willems JL. Clinical management of mustard gas casualties. Ann Med Mil Belg 1989;3(suppl 1): 1-61.
3. Ghanei M, Tazelaar HD, Chilosi M, Harandi AA, Peyman M, Akbari HM, Shamsaei H, Bahadori M, Aslani J, Mohammadi A. An international collaborative pathologic study of surgical lung biopsies from mustard gas-exposed patients. Respir Med 2008;102: 825-830.
4. Watanabe K, Ishida T, Sugawara A, Tachihara M, Munakata M. An adult case of plastic bronchitis. Intern Med 2008;47:1549.
5. Eberlein MH, Drummond MB, Haponik EF. Plastic bronchitis: a management challenge. Am J Med Sci 2008;335: 163-169.
6. Goo HW, Jhang WK, Kim YH, Ko JK, Park IS, Park JJ, Yun TJ, Seo DM. CT findings of plastic bronchitis in children after a Fontan operation. Pediatr Radiol 2008;38: 989-993.
7. Do TB, Chu JM, Berdjis F, Anas NG. Fontan patient with plastic bronchitis treated successfully using aerosolized tissue plasminogen activator: a case report and review of the literature. Pediatr Cardiol 2009;30: 352-355.
8. Costello JM, Steinhorn D, McColley S, Gerber ME, Kumar SP. Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature. Pediatrics 2002; 109:e67.
9. Heath L, Ling S, Racz J, Mane G, Schmidt L, Myers JL, Tsai WC, Caruthers RL, Hirsch JC, Stringer KA. Prospective, longitudinal study of plastic bronchitis cast pathology and responsiveness to tissue plasminogen activator. Pediatr Cardiol 2011;32: 1182-1189.
10. Wakeham MK, Van Bergen AH, Torero LE, Akhter J. Long-term treatment of plastic bronchitis with aerosolized tissue plasminogen activator in a Fontan patient. Pediatr Crit Care Med 2005;6: 76-78.
11. Brogan TV, Finn LS, Pyskaty DJ Jr, Redding GJ, Ricker D, Inglis A, Gibson RL. Plastic bronchitis in children: a case series and review of the medical literature. Pediatr Pulmonol 2002;34: 482-487.
12. Seear M, Hui H, Magee F, Bohn D, Cutz E. Bronchial casts in children: a proposed classification based on nine cases and a review of the literature. Am J Respir Crit Care Med 1997;155: 364-370.
13. Tonan M, Hashimoto S, Kimura A, Matsuyama H, Kinose H, SawadaM, Shime N, Tokuhira N, Kato Y, SasakiM, et al. Successful treatment of severe asthma-associated plastic bronchitis with extracorporeal membrane oxygenation. J Anesth 2012;26: 265-268.
14. Pawar SS, Chun RH, Rao AR, Kerschner JE. Management of plastic bronchitis in a child with mild intermittent asthma. Ann Otol Rhinol Laryngol 2011;120: 697-699.
15. Mateos-Corral D, Cutz E, Solomon M, Ratjen F. Plastic bronchitis as an unusual cause of mucus plugging in cystic fibrosis. Pediatr Pulmonol 2009;44: 939-940.
16. Waring WW, Brunt CH, Hilman BC. Mucoid impaction of the bronchi in cystic fibrosis. Pediatrics 1967;39: 166-175.
17. Moser C, Nussbaum E, Cooper DM. Plastic bronchitis and the role of bronchoscopy in the acute chest syndrome of sickle cell disease. Chest 2001;120: 608-613.
18. Deng J, Zheng Y, Li C, Ma Z, Wang H, Rubin BK. Plastic bronchitis in three children associated with 2009 influenza A(H1N1) virus infection. Chest 2010;138: 1486-1488.
19. Kuperman T, Wexler ID, Shoseyov D, Weintraub M, Revel-Vilk S, Kerem E. Plastic bronchitis caused by neoplastic infiltrates in a child. Pediatr Pulmonol 2006;41: 893-896.
20. Pruitt BA Jr. Complications of thermal injury. Clin Plast Surg 1974;1: 667-691.
21. Cox RA, Burke AS, Soejima K, Murakami K, Katahira J, Traber LD, Herndon DN, Schmalstieg FC, Traber DL, Hawkins HK. Airway obstruction in sheep with burn and smoke inhalation injuries. Am J Respir Cell Mol Biol 2003;29: 295-302.
22. Veress LA, O'Neill HC, Hendry-Hofer TB, Loader JE, Rancourt RC, White CW. Airway obstruction due to bronchial vascular injury after sulfur mustard analog inhalation. Am J Respir Crit Care Med 2010; 182: 1352-1361.
23. Krenke K, Krenke R, Krauze A, Lange J, Kulus M. Plastic bronchitis: an unusual cause of atelectasis. Respiration 2010;80: 146-147.
24. Madsen P, Shah SA, Rubin BK. Plastic bronchitis: new insights and a classification scheme. Paediatr Respir Rev 2005;6: 292-300.
25. Zahorec M, Kovacikova L, Martanovic P, Skrak P, Kunovsky P. The use of high-frequency jet ventilation for removal of obstructing casts in patients with plastic bronchitis. Pediatr Crit Care Med 2009;10:e34-e36.
26. Wang G, Wang YJ, Luo FM, Wang L, Jiang LL, Mao B. Effective use of corticosteroids in treatment of plastic bronchitis with hemoptysis in Chinese adults. Acta Pharmacol Sin 2006;27: 1206-1212.
27. Shinkai M, Rubin BK. Macrolides and airway inflammation in children. Paediatr Respir Rev 2005;6: 227-235.
28. Haseyama K, Satomi G, Yasukochi S, Matsui H, Harada Y, Uchita S. Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg 2006;132: 1232-1233.
29. Desai MH, Mlcak R, Richardson J, Nichols R, Herndon DN. Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine [correction of acetylcystine] therapy. J Burn Care Rehabil 1998;19: 210-212.
30. Silva RC, Simons JP, Chi DH, Yellon RF, Alper CM. Endoscopic treatment of plastic bronchitis. Arch Otolaryngol Head Neck Surg 2011;137: 401-403.
31. Wilson J, Russell J, Williams W, Benson L. Fenestration of the Fontan circuit as treatment for plastic bronchitis. Pediatr Cardiol 2005;26: 717-719.
32. Shah SS, Drinkwater DC, Christian KG. Plastic bronchitis: is thoracic duct ligation a real surgical option? Ann Thorac Surg 2006;81: 2281-2283.
33. Barber BJ, Burch GH, Tripple D, Balaji S. Resolution of plastic bronchitis with atrial pacing in a patient with fontan physiology. Pediatr Cardiol 2004;25: 73-76.
34. Laubisch JE, Green DM, Mogayzel PJ, Reid Thompson W. Treatment of plastic bronchitis by orthotopic heart transplantation. Pediatr Cardiol 2011;32: 1193-1195.
35. Barreto AD, Alexandrov AV, Lyden P, Lee J, Martin-Schild S, Shen L, Wu TC, Sisson A, Pandurengan R, Chen Z, et al. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke 2012;43: 770-775.
36. Kablau M, Alonso A, Hennerici MG, Fatar M. Treatment with tPA predicts better outcome even if MCA occlusion persists. Int J Stroke (In press)
37. Fitchett DH, Theroux P, Brophy JM, Cantor WJ, Cox JL, Gupta M, Kertland H, Mehta SR, Welsh RC, Goodman SG. Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment-part 2: ST-segment elevation myocardial infarction. Can J Cardiol2011 27 (Suppl A):S402-S412.
38. Zeltner TB, Bertacchini M, Messerli A, Burri PH. Morphometric estimation of regional differences in the rat lung. Exp Lung Res 1990;16: 145-158.
39. Gao X, Anderson DR, Brown AW, Lin H, Amnuaysirikul J, Chua AL, Holmes WW, Ray P. Pathological studies on the protective effect of a macrolide antibiotic, roxithromycin, against sulfur mustard inhalation toxicity in a rat model. Toxicol Pathol 2011;39: 1056-1064.
40. Fairhall SJ, Jugg BJ, Read RW, Stubbs SJ, Rutter SJ, Smith AJ, Mann TM, Jenner J, Sciuto AM. Exposure-response effects of inhaled sulfur mustard in a large porcine model: a 6-h study. Inhal Toxicol 2010;22: 1135-1143.
41. O'Neill HC, Orlicky DJ, Hendry-Hofer TB, Loader JE, Day BJ, White CW. Role of reactive oxygen and nitrogen species in olfactory epithelial injury by the sulfur mustard analogue 2-chloroethyl ethyl sulfide. Am J Respir Cell Mol Biol 2011;45: 323-331.
42. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993;329: 1615-1622.
43. Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, Sonnenberg FA, Schulman S, Vandvik PO, Spencer FA, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e601S-e636S.
44. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141:e419S-e494S.
45. Hilleman D, Campbell J. Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review. Pharmacotherapy 2011;31: 1031-1040.
46. Garcia A, Gander JW, Gross ER, Reichstein A, Sheth SS, Stolar CJ, Middlesworth W. The use of recombinant tissue-type plasminogen activator in a newborn with an intracardiac thrombus developed during extracorporeal membrane oxygenation. J Pediatr Surg 2011;46: 2021-2024.
47. Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, Peckham D, Davies CW, Ali N, Kinnear W, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011;365: 518-526.
48. Johnson AR, JensenHL, Peltier G,DelaCruz E. Efficacy of intravenous tissue plasminogen activator in frostbite patients and presentation of a treatment protocol for frostbite patients. Foot Ankle Spec 2011;4: 344-348.
49. van Goor H, Bom VJ, van der Meer J, Sluiter WJ, Geerards S, van der Schaaf W, de Graaf JS, Bleichrodt RP. Pharmacokinetics of human recombinant tissue-type plasminogen activator, administered intraabdominally, in a rat peritonitis model. Eur Surg Res 1996;28: 287-294.
50. Enkhbaatar P, Murakami K, Cox R, Westphal M, Morita N, Brantley K, Burke A, Hawkins H, Schmalstieg F, Traber L, et al. Aerosolized tissue plasminogen inhibitor improves pulmonary function in sheep with burn and smoke inhalation. Shock 2004;22: 70-75.